Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Edwards Announces Key Events For PCR London Valves 2017 | ||
By: PR Newswire Association LLC. - 24 Sep 2017 | Back to overview list |
|
LONDON, Sept. 24, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced key events for the company during the PCR London Valves 2017 course, as the meeting celebrates 15 years of transcatheter aortic valve replacement. Among the scheduled events and data presentations are:
"As PCR London Valves celebrates 15 years of transcatheter aortic valve replacement, Edwards is proud to have led the development and evolution of TAVR as a preferred therapy for patients in need around the world," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves. The Edwards SAPIEN 3 Ultra System and CENTERA Transcatheter Heart Valve System are not currently available for commercial sale in any country. About Edwards Lifesciences This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements regarding expected future product approvals, dates of commercial availability and expected benefits and results. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors, including but not limited to, unexpected outcomes after longer term clinical experience with the product; or unanticipated quality, manufacturing or regulatory delays or issues. These factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2016. These filings, along with important safety information about our products, may be found at edwards.com. Edwards, Edwards Lifesciences, the stylized E logo, Axela, Cardioband, CENTERA, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. View original content with multimedia:http://www.prnewswire.com/news-releases/edwards-announces-key-events-for-pcr-london-valves-2017-300524703.html SOURCE Edwards Lifesciences Corporation |
||
|
||
Copyright 2017 PR Newswire Association LLC. | Back to overview list |